TG Therapeutics, Inc.

TG Therapeutics, Inc.

TGTXNYSE / NASDAQHealthcareMid cap

$63.34-$1.54 (-2.4%)

Last close · Data as of Nov 20, 2026

Market cap
$6.2B
P/E
13.9x
EV / EBITDA
47.5x
Revenue
$616.3M
Net margin
72.6%
ROCE
13.6%

+108.0% over the last year

TG Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+16.2%
3M
+25.3%
6M
+59.3%
1Y
+108.0%
5Y
+159.5%

52-week range

Day change -$1.54 (-2.4%) from $65 to $63 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in TGTX, bought on each weekday since 2021.

News & filings

What TG Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOperating cash flow was -24.8 million US dollars in fiscal 2025, a year of net profit.

Strengths (1)

  • Net margin of 72.6% against a peer median of 9.3%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.

Read moreShow less

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Sector
Healthcare
Shares outstanding
144.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$6.2B
P/E
13.9x
P/B
9.6x
EV / EBITDA
47.5x
EV / Sales
10.4x
P/S
10.1x
52-week high
$66.12
52-week low
$26.94

Profitability

Operating margin
20.0%
Net margin
72.6%
EBITDA margin
21.8%
ROE
69.0%
ROCE
13.6%
ROA
42.1%
Asset turnover
0.58

Growth

Revenue
$616.3M
Revenue growth, 1Y
87.3%
Revenue CAGR, 3Y
504.9%
Net profit growth, 1Y
1812.4%
Free cash flow
-$25.0M

Solvency

Current ratio
4.10
Debt / Equity
0.39
Debt / Assets
0.24
CFO / Net profit
-0.06
Cash / Market cap
1.3%

Where the revenue went

Of every $100 of FY2025 revenue, $73 was left as net income.

TG Therapeutics, Inc. income statement flow, FY2025
TG Therapeutics, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$100.7M
RevenueGross profit$515.6M
Gross profitResearch and development$160.2M
Gross profitSelling, general and administrative$232.0M
Gross profitOther operating expenses$10.0k
Gross profitOperating income$123.3M
Operating incomePretax income$107.4M
Operating incomeInterest and other expense$15.9M
Pretax incomeNet income$107.4M
Tax benefit and otherNet income$339.8M

Revenue and net profit

Revenue grew 87.3% in FY2025; net profit is the dashed line.

TG Therapeutics, Inc. revenue and net profit by fiscal year
TG Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$2.8M-$223.8M
FY2023$233.7M$12.7M
FY2024$329.0M$23.4M
FY2025$616.3M$447.2M

Cash flows

FY2025: -$24.8M from operations, -$25.0M free after investment (dashed).

TG Therapeutics, Inc. operating and free cash flow by fiscal year
TG Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$176.2M-$176.2M
FY2023-$31.4M-$31.4M
FY2024-$40.5M-$40.6M
FY2025-$24.8M-$25.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$616.3M+87.3%1Y
EBITDA
$134.4M+169.2%1Y
Net profit
$447.2M+1,812.4%1Y
Cash from operations
-$24.8M
Free cash flow
-$25.0M
Revenue CAGR, 3Y
504.9%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$616.3M$134.4M$447.2M-$25.0M69.0%+87.3%+1812.4%

Monthly returns

Month-by-month returns of TGTX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.1B
Liabilities$415.2M
Equity$648.0M
Paid-in capital$1.8B
Retained earnings-$1.1B
Treasury stock$100.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; TGTX highlighted.

P/E against peers

TGTX trades at 13.9x earnings against a peer median of 14.8x.

Not shown (no positive earnings and no EV / Sales): Glaukos Corporation, Protagonist Therapeutics, Inc., Teleflex Incorporated.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
TG Therapeutics, Inc.TGTXthis company$6.2B13.9x9.6x69.0%47.5x
Alkermes plcALKS$7.2B29.9x4.0x13.3%20.9x
Glaukos CorporationGKOS$7.1B-38.1x10.9x-28.6%-49.0x
Protagonist Therapeutics, Inc.PTGX$6.6B-50.8x10.8x-21.2%-41.4x
PTC Therapeutics, Inc.PTCT$5.9B8.6x—-332.5%7.5x
Teleflex IncorporatedTFX$5.8B-6.5x1.9x-29.0%27.1x
Apellis Pharmaceuticals, Inc.APLS$5.3B234.6x14.2x6.0%75.2x
Ligand Pharmaceuticals IncorporatedLGND$4.7B38.0x4.6x12.2%25.3x
Indivior Pharmaceuticals, Inc.INDV$4.4B21.1x-44.7x-212.1%15.1x
Peer median—14.8x4.6x-24.9%18.0x

Year-to-date ROI

TGTX since 1 January, against earlier years.

Historical volatility

TGTX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

TG Therapeutics, Inc. operating margin by fiscal year
TG Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-7853.2%
FY20238.8%
FY202412.7%
FY202520.0%
LineFY2025
Cost of revenueCost Of Revenue$100.7M
Gross profitGross Profit$515.6M
Operating expensesOperating Expense$392.3M
Research and developmentResearch And Development$160.2M
Total expensesTotal Expenses$493.0M
Pretax incomePretax Income$107.4M

Learn while you research

Academy chapters picked for TG Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Growth Investing87% revenue growth is in the top tier, learn how to value growth.7 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →